Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing.

Whitehead TA, Chevalier A, Song Y, Dreyfus C, Fleishman SJ, De Mattos C, Myers CA, Kamisetty H, Blair P, Wilson IA, Baker D.

Nat Biotechnol. 2012 May 27;30(6):543-8. doi: 10.1038/nbt.2214.

2.

Next-generation protein engineering targets influenza.

Wodak SJ.

Nat Biotechnol. 2012 Jun 7;30(6):502-4. doi: 10.1038/nbt.2268. No abstract available.

PMID:
22678386
3.

Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.

Chen X, Si L, Liu D, Proksch P, Zhang L, Zhou D, Lin W.

Eur J Med Chem. 2015 Mar 26;93:182-95. doi: 10.1016/j.ejmech.2015.02.006. Epub 2015 Feb 7.

PMID:
25681711
4.

Discovering neutralizing antibodies targeting the stem epitope of H1N1 influenza hemagglutinin with synthetic phage-displayed antibody libraries.

Tung CP, Chen IC, Yu CM, Peng HP, Jian JW, Ma SH, Lee YC, Jan JT, Yang AS.

Sci Rep. 2015 Oct 12;5:15053. doi: 10.1038/srep15053.

5.

Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.

Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL.

ACS Infect Dis. 2017 May 12;3(5):330-335. doi: 10.1021/acsinfecdis.6b00194. Epub 2017 Apr 3.

PMID:
28301927
6.

Identification of small molecules acting against H1N1 influenza A virus.

Agamennone M, Pietrantoni A, Superti F.

Virology. 2016 Jan 15;488:249-58. doi: 10.1016/j.virol.2015.11.024. Epub 2015 Dec 3.

7.

Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral Hemagglutinin.

Sato Y, Morimoto K, Kubo T, Sakaguchi T, Nishizono A, Hirayama M, Hori K.

Mar Drugs. 2015 May 29;13(6):3454-65. doi: 10.3390/md13063454.

8.

Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy.

Matsubara T, Onishi A, Saito T, Shimada A, Inoue H, Taki T, Nagata K, Okahata Y, Sato T.

J Med Chem. 2010 Jun 10;53(11):4441-9. doi: 10.1021/jm1002183.

PMID:
20476787
9.

Inhibition of influenza virus infection and hemagglutinin cleavage by the protease inhibitor HAI-2.

Hamilton BS, Chung C, Cyphers SY, Rinaldi VD, Marcano VC, Whittaker GR.

Biochem Biophys Res Commun. 2014 Jul 25;450(2):1070-5. doi: 10.1016/j.bbrc.2014.06.109. Epub 2014 Jun 27.

10.

Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.

Wang H, Xu R, Shi Y, Si L, Jiao P, Fan Z, Han X, Wu X, Zhou X, Yu F, Zhang Y, Zhang L, Zhang L, Zhou D, Xiao S.

Eur J Med Chem. 2016 Mar 3;110:376-88. doi: 10.1016/j.ejmech.2016.01.005. Epub 2016 Jan 8.

PMID:
26866456
11.

Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds.

Torres E, Duque MD, Vanderlinden E, Ma C, Pinto LH, Camps P, Froeyen M, Vázquez S, Naesens L.

Antiviral Res. 2013 Sep;99(3):281-91. doi: 10.1016/j.antiviral.2013.06.006. Epub 2013 Jun 22.

PMID:
23800838
12.

Inhibition of influenza virus infection by multivalent pentacyclic triterpene-functionalized per-O-methylated cyclodextrin conjugates.

Tian Z, Si L, Meng K, Zhou X, Zhang Y, Zhou D, Xiao S.

Eur J Med Chem. 2017 Jul 7;134:133-139. doi: 10.1016/j.ejmech.2017.03.087. Epub 2017 Apr 2.

PMID:
28411453
13.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

14.

Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM.

J Virol. 2016 Apr 14;90(9):4720-34. doi: 10.1128/JVI.03152-15. Print 2016 May.

15.

Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus.

Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, Ruigrok RW, Di Primo C, Slama-Schwok A.

Antimicrob Agents Chemother. 2013 May;57(5):2231-42. doi: 10.1128/AAC.02335-12. Epub 2013 Mar 4.

16.

Genetic requirement for hemagglutinin glycosylation and its implications for influenza A H1N1 virus evolution.

Kim JI, Lee I, Park S, Hwang MW, Bae JY, Lee S, Heo J, Park MS, García-Sastre A, Park MS.

J Virol. 2013 Jul;87(13):7539-49. doi: 10.1128/JVI.00373-13. Epub 2013 May 1.

17.

Structurally conserved binding sites of hemagglutinin as targets for influenza drug and vaccine development.

Yusuf M, Konc J, Sy Bing C, Trykowska Konc J, Ahmad Khairudin NB, Janezic D, Wahab HA.

J Chem Inf Model. 2013 Sep 23;53(9):2423-36. doi: 10.1021/ci400421e. Epub 2013 Sep 13.

PMID:
23980878
18.

Discovery of a new class of antiviral compounds: camphor imine derivatives.

Sokolova AS, Yarovaya OI, Shernyukov AV, Gatilov YV, Razumova YV, Zarubaev VV, Tretiak TS, Pokrovsky AG, Kiselev OI, Salakhutdinov NF.

Eur J Med Chem. 2015 Nov 13;105:263-73. doi: 10.1016/j.ejmech.2015.10.010. Epub 2015 Oct 22.

PMID:
26498572
19.

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity.

Wang W, DeFeo CJ, Alvarado-Facundo E, Vassell R, Weiss CD.

J Virol. 2015 Oct;89(20):10602-11. doi: 10.1128/JVI.00939-15. Epub 2015 Aug 12.

20.

Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction.

Musafia B, Oren-Banaroya R, Noiman S.

PLoS One. 2014 May 20;9(5):e97696. doi: 10.1371/journal.pone.0097696. eCollection 2014.

Supplemental Content

Support Center